Get to know our clinical trials
Clinical trial of PF-06863135 in monotherapy in participants with multiple myeloma resistant to at least one proteasome inhibitor, an immunomodulatory drug and an anti-cd38 antibody.
THE PURPOSE OF THIS STUDY IS TO FIND OUT THE EFFECTS OF THE STUDY DRUG (PF-06863135) IN THE TREATMENT OF MULTIPLE MYELOMA. THE STUDY DRUG (PF-06863135) IS AN INVESTIGATIONAL DRUG BECAUSE IT HAS NOT BEEN APPROVED FOR USE IN THIS COUNTRY. THE STUDY DRUG IS COMPOSED OF TWO ANTIBODIES (SOMETIMES REFERRED TO AS A &IQUEST;BI-SPECIFIC ANTIBODY&IQUEST;). THE STUDY DRUG BINDS TO T-LYMPHOCYTES (A TYPE OF IMMUNE SYSTEM CELL) AND MYELOMA CELLS, CAUSING THE T-LYMPHOCYTES TO DESTROY THE MYELOMA CELLS.
- OPEN-LABEL, MULTICENTER, NONRANDOMIZED PHASE II STUDY OF PF-06863135 IN MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
- Code EudraCT: 2020-004533-21
- Protocol number: C1071003
- Promoter: Pfizer
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.